Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This study tested whether adding an immunotherapy drug (pembrolizumab) to a standard tumor-destroying procedure (ablation) could better control early-stage liver cancer. It involved 30 patients eligible for ablation, aiming to see if the combination could shrink tumors before the…

This study tested a new drug for people with advanced stomach or esophageal cancer that had spread and stopped responding to standard treatments. The drug, called sacituzumab-govitecan, is designed to target cancer cells specifically. Researchers gave the drug to 58 patients to s…

This study created a permanent registry to collect information from people with bile duct cancer in Germany. It tracked what treatments patients received, how they felt, and how the disease progressed, but did not test any new treatments. The goal was to gather real-world data to…